Biotech4 months ago
Crown Laboratories Buys Revance Therapeutics for $924 Million
Crown Laboratories is acquiring Revance Therapeutics to expand its presence in the beauty market, offering $6.66 per share, an 89% premium. Revance, maker of the Botox...